Cargando…

The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells

The B-cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). By global microRNA profiling of CLL cells stimulated or not stimulated by anti-IgM, significant up-regulation of microRNAs from the miR-132~212 cluster was observed both in IG...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dal Bo, Michele, D'Agaro, Tiziana, Gobessi, Stefania, Zucchetto, Antonella, Dereani, Sara, Rossi, Davide, Zaja, Francesco, Pozzato, Gabriele, Di Raimondo, Francesco, Gaidano, Gianluca, Laurenti, Luca, Del Poeta, Giovanni, Efremov, Dimitar G., Gattei, Valter, Bomben, Riccardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662478/ https://www.ncbi.nlm.nih.gov/pubmed/26036258

Ejemplares similares

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia
por: Dereani, Sara, et al.
Publicado: (2014)

Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance
por: Dal-Bo, Michele, et al.
Publicado: (2009)

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
por: Pozzo, Federico, et al.
Publicado: (2013)

SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation
por: Pozzo, Federico, et al.
Publicado: (2020)

IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia
por: Bulian, Pietro, et al.
Publicado: (2012)

TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?
por: Bomben, Riccardo, et al.
Publicado: (2023)

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
por: Bomben, Riccardo, et al.
Publicado: (2023)

KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival
por: Vendramini, Elena, et al.
Publicado: (2019)

Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models
por: Capolla, Sara, et al.
Publicado: (2023)

HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia
por: Griggio, Valentina, et al.
Publicado: (2020)

Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukemia
por: Del Poeta, Giovanni, et al.
Publicado: (2020)

Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance
por: Zucchetto, Antonella, et al.
Publicado: (2006)

A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial
por: Bomben, Riccardo, et al.
Publicado: (2018)

Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells
por: Rossi, Francesca M, et al.
Publicado: (2010)

P594: THE CXCR4-LOW/CD5-HIGH PROLIFERATIVE FRACTION IS ENRICHED IN BTK MUTATIONS AND ANTICIPATES RELAPSE IN IBRUTINIB-TREATED CLL
por: Pozzo, Federico, et al.
Publicado: (2023)

Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia
por: Wang, Jiguang, et al.
Publicado: (2014)

A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia
por: Cohen, Jared A., et al.
Publicado: (2020)

KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders
por: Vendramini, Elena, et al.
Publicado: (2022)

Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study
por: Benintende, Giulia, et al.
Publicado: (2022)

The MYC/miR-17-92 axis in lymphoproliferative disorders: A common pathway with therapeutic potential
por: Dal Bo, Michele, et al.
Publicado: (2015)

VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects
por: Härzschel, Andrea, et al.
Publicado: (2020)

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy
por: Cohen, Jared A., et al.
Publicado: (2020)

Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia
por: Tissino, Erika, et al.
Publicado: (2018)

Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond
por: Pozzo, Federico, et al.
Publicado: (2022)

Therapeutic Targets in Chronic Lymphocytic Leukemia
por: Laurenti, Luca, et al.
Publicado: (2020)

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
por: Laurenti, Luca, et al.
Publicado: (2016)

Corticosteroids do not cause harmful increase of viral load in severe H1N1 virus infection
por: Confalonieri, Marco, et al.
Publicado: (2010)

Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
por: Monti, Paola, et al.
Publicado: (2020)

Isolation and Full-Length Genome Characterization of SARS-CoV-2 from COVID-19 Cases in Northern Italy
por: Licastro, Danilo, et al.
Publicado: (2020)

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies
por: Pepper, Andrea G. S., et al.
Publicado: (2021)

Integrin Signaling Shaping BTK-Inhibitor Resistance
por: Polcik, Laura, et al.
Publicado: (2022)

The Use of Monoclonal Antibodies in the Treatment of Autoimmune Complications of Chronic Lymphocytic Leukemia
por: Laurenti, Luca, et al.
Publicado: (2013)

Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL
por: Efremov, Dimitar G., et al.
Publicado: (2012)

Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies
por: Efremov, Dimitar G., et al.
Publicado: (2020)

Measurable residual disease in chronic lymphocytic leukemia
por: Benintende, Giulia, et al.
Publicado: (2023)

P606: MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL
por: Vit, Filippo, et al.
Publicado: (2023)

Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases
por: Mazzaro, Cesare, et al.
Publicado: (2018)

Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab
por: Ballotta, Laura, et al.
Publicado: (2022)

Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2
por: Malipiero, Giacomo, et al.
Publicado: (2022)

CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms
por: Hutterer, Evelyn, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_07causo2h5tgi7o53nlunl3j97